MentalHealthDaily

How People Feel About Antipsychotics & Mood Stabilizers: Twitter/X Sentiment Analysis (2024 Study)

by GLOOM

Social media has emerged as a pivotal source of real-world evidence, especially in understanding patient experiences and perceptions regarding the treatment of severe mental disorders such as Schizophrenia and related psychotic disorders (SRD) and Bipolar Disorder (BD). Leveraging advanced artificial intelligence (AI) techniques, a comprehensive analysis of 893,289 tweets between 2008 and 2022 revealed significant …

Cannabis (Marijuana) Use & Psychosis: Does It Increase Risk? (2023 Evidence Review)

by GLOOM

The relationship between cannabis (marijuana) use and psychosis has been a topic of considerable scientific interest and public health concern. With changing legal statuses and societal attitudes towards cannabis use in many countries, understanding this relationship is more critical than ever. Highlights: Systematic reviews and meta-analyses show a consistent association between cannabis use and increased …

Genetic (Polygenic) Risk for Psychiatric Disorders & Subject-Specific School Grades (2023 Study)

by GLOOM

The intricate connection between mental health and educational attainment is a subject of growing interest and importance. Recent studies have shed light on how genetic predispositions to certain mental disorders can influence academic performance, challenging our understanding of how mental health impacts learning. Highlights: Polygenic Risk Scores Reveal New Insights: Studies utilizing polygenic risk scores …

Genetic Risk for Low Vitamin D Linked to Lower Social Motivation in First-Episode Psychosis (2024 Study)

by GLOOM

Recent research reveals a notable association between vitamin D levels and the severity of negative symptoms in individuals with first-episode psychosis (FEP). A new study explored the genetic predisposition towards lower vitamin D levels and its impact on symptom severity in schizophrenia and related disorders. Highlights: Vitamin D & Psychosis Connection: Lower levels of vitamin …

Probiotics & Synbiotics for the Metabolic Side Effects of Psychiatric Medications: Are They Effective? (2024 Review)

by GLOOM

Patients with severe mental illnesses (SMI), such as schizophrenia and chronic depression, often face the challenge of managing weight gain and metabolic complications, side effects commonly associated with antipsychotics and antidepressants. These medications are known to induce increased appetite and weight gain, leading to long-term metabolic syndromes. Recent studies have evaluated into the role of …

MicroRNA Biomarkers May Help Diagnose Schizophrenia

by GLOOM

Schizophrenia (SZ) is a complex psychiatric disorder characterized by a myriad of symptoms, typically divided into positive, negative, and cognitive categories. Despite the prevalence and severity of this condition, current diagnostic methods are largely based on subjective clinical interviews and observations, leading to potential misdiagnosis and delayed treatment. Recent studies have focused on microRNAs (miRNAs) …

BPC-157 Peptide for Neurological & CNS Disorders: Preliminary Research

by GLOOM

BPC 157, a stable gastric pentadecapeptide, has recently emerged as a promising therapeutic agent due to its multifaceted role in treating various central nervous system disorders. Its ability to mitigate conditions like stroke, schizophrenia, and spinal cord injuries while promoting neural recovery and functional improvement is capturing the interest of the medical community. Highlights: BPC …